- Possessing human genome and microbiome data in all clinical stages- Becoming a global bio-healthcare big data platform company

-在所有临床阶段拥有人类基因组和微生物组数据-成为全球生物保健大数据平台公司

SEOUL, South Korea, Dec. 20, 2023 /PRNewswire/ -- Dx&Vx will develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS.

韩国首尔，2023年12月20日/PRNewswire/--Dx＆Vx将利用LG CNS提供的AI技术开发生物保健大数据平台。

Dx&Vx recently announced on the 18th that it has signed a contract with LG CNS to jointly develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS. This is the first case of LG CNS collaborating with a domestic pharma-bio company.

Dx&Vx最近于18日宣布，已与LG CNS签署合同，利用LG CNS提供的人工智能技术，共同开发生物保健大数据平台。这是LG CNS与国内制药生物公司合作的第一例。

Dx&Vx is set to introduce an AI-driven digital medical and clinical data platform through its collaboration with LG CNS. LG CNS is a Google Cloud partner and key service provider. LG CNS will provide the AI and big data technologies needed to build the platform.

Dx＆Vx将通过与LG CNS的合作引入AI驱动的数字医疗和临床数据平台。LG CNS是谷歌云合作伙伴和关键服务提供商。LG CNS将提供构建平台所需的人工智能和大数据技术。

Through its cloud-based a precision medicine data platform, Dx&Vx has built a bio big data bridge system with Clidex CDx, a companion diagnostic (CDx) service, to provide a clinical decision support system (CDSS), Digital Therapeutics (DTx), and digital twin-based remote medicine, and will expand its service sales network to global markets such as new drug developers and pharmaceutical companies, medical institutions, and research institutes that need to provide precision medicine-based multi-omics analysis data and develop therapeutic drugs and related healthcare solutions..

Dx&Vx通过其基于云的精准医学数据平台，与伴随诊断（CDx）服务Clidex CDx建立了生物大数据桥梁系统，以提供临床决策支持系统（CDSS）、数字治疗（DTx）和基于数字双胞胎的远程医学，并将其服务销售网络扩展到全球市场，如新药开发商和制药公司，需要提供基于精准医学的多组学分析数据并开发治疗药物和相关医疗保健解决方案的医疗机构和研究机构。。

Dx&Vx has more than 440,000 genomic analysis data, the largest in Korea. The data is clinical and genomic big data for clinical diagnosis and includes human genomic data and microbiome data in clinical stages, including embryonic stem cells for preimplantation genomic test, abortus tissues, cell free fetal DNA, amniocytes and chorionic villus sampling (CVS) tissues , blood and tissues of neonates, adults, and cancer cells. .

Dx＆Vx拥有超过440000个基因组分析数据，是韩国最大的。该数据是用于临床诊断的临床和基因组大数据，包括临床阶段的人类基因组数据和微生物组数据，包括用于植入前基因组测试的胚胎干细胞，流产组织，无细胞胎儿DNA，羊膜细胞和绒毛膜绒毛取样（CVS）组织，新生儿，成人和癌细胞的血液和组织。。

In particular, it contains clinical data of various disease group as well as reference group, and is highly reliable and scalable for the discovery of disease subtype-specific biomarkers for various cancer, rare disease and infectious disease research, as well as for the development of therapeutics and identification of mechanisms of action according to genetic differences among ethnic groups, gender-omics and age differences..

特别是，它包含各种疾病组和参考组的临床数据，对于发现各种癌症，罕见病和传染病研究的疾病亚型特异性生物标志物，以及根据种族之间的遗传差异开发治疗方法和确定作用机制，具有高度可靠性和可扩展性，性别组学和年龄差异。。

'Currently, we are implementing artificial intelligence (AI) algorithm in new drug development projects to increase the possibility of success in new drugs development, and we are expanding collaboration with domestic and foreign IT companies to expand related services. This joint development will be the starting point for Dx&Vx to grow into a global integrated biomedical big data-based bio-healthcare personalized precision medicine solution provider,' said an official from Dx&Vx..

“目前，我们正在新药开发项目中实施人工智能（AI）算法，以增加新药开发成功的可能性，我们正在扩大与国内外IT公司的合作，以扩大相关服务。Dx＆Vx的一位官员表示，此次联合开发将是Dx＆Vx成长为基于全球集成生物医学大数据的生物保健个性化精准医学解决方案提供商的起点。。

Starting with the joint development, Dx&Vx plans to strengthen its collaboration with LG CNS to develop innovative bio-healthcare solutions based on its biomedical big data platform.

从联合开发开始，Dx和Vx计划加强与LG CNS的合作，以基于其生物医学大数据平台开发创新的生物保健解决方案。

Meanwhile, global pharmaceutical giant GSK recently invested $300 million in genomic analysis company 23andME to develop new drugs using genomic information, and the Korea Bio Association predicts that the global genomic market will grow to $13.55 billion in 2024.

与此同时，全球制药巨头葛兰素史克（GSK）最近向基因组分析公司23andME投资3亿美元，利用基因组信息开发新药，韩国生物协会（Korea Bio Association）预测，2024年全球基因组市场将增长至135.5亿美元。

SOURCE Dx&Vx

源Dx和Vx